An AI Scientist Proposed an ADHD Treatment on the Blockchain: BIO Price Surges

By: crypto insight|2026/04/17 19:00:02
0
Share
copy

Key Takeaways:

  • Bio Protocol’s crypto has soared 90% following a $6.9M funding boost for its AI-native platform, Bio V2.
  • The funding was led by Maelstrom Fund and aims to facilitate onchain fundraising and autonomous AI co-scientists.
  • Bio Protocol’s scientific proposal for an ADHD treatment targeting orexin receptors drove excitement in crypto-science circles.
  • BIO’s recent price spike of 40% from a low-liquidity range highlights volatility in DeSci investments.
  • LiquidChain is developing cross-chain infrastructure to support emerging DeSci and DeFi applications.

WEEX Crypto News, 2026-04-17 07:14:58

Decentralized Science and BIO Crypto’s Surge

Bio Protocol crypto recently experienced a staggering 90% price increase, catalyzed by substantial funding advancements and innovative AI applications. With a $6.9 million financial injection from Maelstrom Fund, Bio V2—a full-stack AI-native platform—was positioned at the forefront, promising onchain fundraising capabilities and AI-driven co-scientists, known as BioAgents. This development is a significant step forward in decentralized science (DeSci), capturing the focus of traders and scientists alike.

The spotlight shone further as Bio Protocol’s scientific team proposed a peptide targeting ADHD, sparking interest across crypto-science communities. Studies have shown that ADHD patients have lower levels of orexin-A/B, key in regulating arousal and attention. While existing treatments suppress orexin activity, Bio Protocol and @peptai_ have developed a peptide labeled OX2R-004, aiming to activate the OX2R receptor—potentially redefining ADHD treatment.

Can Bio Protocol Maintain Its Bullish Momentum?

Bio Protocol’s bold 40% price surge emerged from a low-liquidity environment, typifying DeSci’s high volatility. This sudden leap, while exciting, lacked a firm technical foundation, leading to questions about whether the spike can be sustained or will retract. Such moves are often followed by a period of consolidation or a partial pullback, determined by the balance between hype-driven interests and tangible utility.

Currently, BIO finds itself at an intersection between heightened interest and practical utility. To ensure a lasting price escalation, demand must translate into real-world usage, sustaining momentum as the narrative surpasses mere speculation. However, if Bio V2 fails to deliver measurable impact, the price may revert to its pre-announcement level. The broader crypto market also plays a role; downward trends in related tokens could influence BIO, potentially triggering a broader decline.

The Role of LiquidChain in DeSci’s Growth

LiquidChain has emerged as a potential game-changer in bridging the gap between decentralized science and decentralized finance applications. It’s constructing a Layer 3 protocol that combines Bitcoin’s financial strength, Ethereum’s DeFi capabilities, and Solana’s execution speed into a single, cohesive liquidity environment, without the need for asset wrapping. This innovation is key to supporting multi-chain DeSci initiatives.

LiquidChain’s architecture enables developers to create applications once and tap into user bases across multiple ecosystems—an attractive proposition for DeSci and DeFi projects. As of now, $674,947.04 has been raised in its presale, with tokens priced at $0.0145. However, presales harbor risks; success hinges on broader adoption rates, while premature entries have diminishing returns once catalysts are publicly realized.

-- Price

--

FAQ Section

What caused Bio Protocol’s price to surge by 90%?

Bio Protocol’s price increased due to a $6.9 million funding round for its AI-native platform, Bio V2, backed by Maelstrom Fund. This elevated efforts for onchain fundraising and the involvement of AI co-scientists, attracting significant interest.

Is Bio Protocol’s ADHD treatment scientifically promising?

Bio Protocol’s ADHD treatment focuses on activating the OX2R receptor with a peptide, OX2R-004. This contrasts current treatments which suppress orexin activity, offering a scientifically provocative approach to ADHD.

Can Bio Protocol sustain its current price level?

To maintain its price, Bio Protocol needs continuous demand linked to practical usage and proven utility of its platform. Hype alone can cause the price to revert once interest wanes.

What does LiquidChain offer to DeSci and DeFi projects?

LiquidChain facilitates a unified liquidity environment across blockchain ecosystems—Bitcoin, Ethereum, and Solana—thereby supporting DeSci and DeFi applications through its deploy-once framework without asset wrapping.

Are there risks associated with investing in LiquidChain’s presale?

LiquidChain’s presale carries risks, particularly due to adoption uncertainties. The potential for low initial market listings and reliance on sustained infrastructure integration poses investment challenges.

You may also like

a16z founder's Stanford lecture: Whenever Wall Street and Silicon Valley have different ideas, it's Wall Street that ends up being wrong

Ben Horowitz, co-founder of a16z, delivered a powerful talk: The two traditional moats of software in the AI era have been erased, and entrepreneurs must seek "new barriers" beyond code and UI.

Michael Saylor: After three consecutive quarters of losses, Strategy will sell Bitcoin to pay dividends

After MSTR's financial report showed continued net losses, Saylor changed his stance: Bitcoin is no longer "never to be sold" and can be used as a payment tool.

The toll station at Hormuz and the RMB that cannot be bought

The disorder of the US dollar is giving rise to a new situation in global settlement: gold is being redefined as a "bridge," the CIPS system is expanding rapidly, and global funds are quietly opening up a new channel for the renminbi, which is "hard to obtain."

Interview with Coinbase Institutional's Strategic Head: The Institutionalization of Crypto Reaches a Critical Point

Coinbase executives provide an in-depth analysis: Unfazed by short-term market panic, institutions are accelerating their entry, and tokenization along with the "exchange of everything" is about to completely reconstruct the global financial infrastructure.

Dialogue with Agora CEO Nick: The battle for stablecoin licenses has just begun

Agora strikes: officially applies for a federal trust bank license in the United States, elevating from a stablecoin issuer to "underlying financial infrastructure," targeting the trillion-dollar enterprise payment and B2B settlement market.

Morning Report | a16z Crypto completes $2.2 billion fundraising for its fifth fund; Bullish invests $4.2 billion to acquire share transfer agency Equiniti; PayPal's Q1 performance exceeds expectations

Overview of Important Market Events on May 5th

Popular coins

Latest Crypto News

Read more
iconiconiconiconiconiconicon
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Program:support@weex.com